- Home
- PKBK vs CLLS Comparison
PKBK vs CLLS Comparison
Compare PKBK & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKBK
- CLLS
- Stock Information
- Founded
- PKBK 1999
- CLLS 1999
- Country
- PKBK United States
- CLLS France
- Employees
- PKBK N/A
- CLLS N/A
- Industry
- PKBK Major Banks
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- PKBK Finance
- CLLS Health Care
- Exchange
- PKBK Nasdaq
- CLLS Nasdaq
- Market Cap
- PKBK 249.7M
- CLLS 240.2M
- IPO Year
- PKBK N/A
- CLLS 2007
- Fundamental
- Price
- PKBK $23.01
- CLLS $1.76
- Analyst Decision
- PKBK
- CLLS Buy
- Analyst Count
- PKBK 0
- CLLS 3
- Target Price
- PKBK N/A
- CLLS $7.00
- AVG Volume (30 Days)
- PKBK 18.6K
- CLLS 70.4K
- Earning Date
- PKBK 10-18-2024
- CLLS 11-04-2024
- Dividend Yield
- PKBK 3.15%
- CLLS N/A
- EPS Growth
- PKBK N/A
- CLLS N/A
- EPS
- PKBK 2.34
- CLLS N/A
- Revenue
- PKBK $63,151,000.00
- CLLS $36,042,000.00
- Revenue This Year
- PKBK N/A
- CLLS $271.02
- Revenue Next Year
- PKBK N/A
- CLLS $33.48
- P/E Ratio
- PKBK $9.96
- CLLS N/A
- Revenue Growth
- PKBK N/A
- CLLS 46.96
- 52 Week Low
- PKBK $15.24
- CLLS $1.70
- 52 Week High
- PKBK $23.44
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- PKBK 66.50
- CLLS 41.97
- Support Level
- PKBK $20.88
- CLLS $1.70
- Resistance Level
- PKBK $23.44
- CLLS $1.90
- Average True Range (ATR)
- PKBK 0.43
- CLLS 0.11
- MACD
- PKBK 0.17
- CLLS 0.00
- Stochastic Oscillator
- PKBK 74.10
- CLLS 33.33
About PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.